Allergy/Asthma News

CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

As wildfires continue to spread across the Los Angeles area, residents with asthma and other respiratory diseases face increased risks to their health.

Gestational diabetes led to an increased risk for asthma exacerbations during pregnancy among a cohort of women with pre-existing asthma, according to results of a retrospective cohort study.

Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.

Children with asthma who visited an allergy specialist were 21% less likely to visit the ED or be hospitalized compared with children who did not, according to findings published in The Journal of Pediatrics.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 weeks of treatment, with responses as early as week 1, according to an online presentation by Jasper Therapeutics.